Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Type 2 diabetes is an illness in which the body does not produce or respond correctly to insulin, an important hormone that transforms glucose into the energy that the body needs to work. People with diabetes are prone to suffer other illnesses and this makes its forecast worse. Type 2 diabetes affects over 5% of adults in the world (250 million people). It is estimated that by 2025 this will have doubled. Medical treatment can’t cure diabetes. However, bariatric surgery cures diabetes in morbidly obese patients and this is not related to weight loss, so it would cure diabetes in non morbidly obese patients. It is observed that glucose tolerance improved in diabetic patient after a gastrectomy and the immediacy of that improvement appeared to be due to the involvement of hormones that control insulin secretion. This showed that the diabetes cure was linked to hormone alterations in the small intestine because of the food transit variation, stimulating insulin secretion in the pancreas. The aim of this study is to assess the effects of a surgical treatment consisting of a stomach reduction and a biliopancreatic bypass that redirects the food to avoid the first section of the intestine and go directly to the last part. This act stimulates natural insulin secretion.

Who can participate?
Patients aged between 18 and 60 with type 2 diabetes.

What does the study involve?
Participants will be randomly allocated into one of two groups. One group will receive the surgical treatment described above and the other group will receive the standard drug treatment for diabetes.

What are the possible benefits and risks of participating?
There could be adverse events related to the surgery (chance of death below 2%, serious complications in around 7% and minor complications in around 17%) and also a reduction of the vitamins absorbed in the digestion that could be solved by taking vitamin supplements.

Where is the study run from?
Royo Vilanova Hospital (Spain).

When is study starting and how long is it expected to run for?
The study started in February 2012 and will finish 14 months later.

Who is funding the study?
Aragon Institute of Health Sciences (Spain).

Who is the main contact?
José Antonio Fatás Cabeza

Trial website

Contact information



Primary contact

Dr José Antonio Fatás Cabeza


Contact details

Servicio de Cirugía General y del Aparato Digestivo
Hospital Royo Vilanova
Avenida San Gregorio 30

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Study and results of a laparoscopic biliopancreatic diversion modality for diabetes type 2 treatment in patients with a BMI between 30 and 35: a randomized prospective clinical trial


Study hypothesis

The minimally invasive surgical technique proposed by the research team prevents the passage of food into the duodenum and causes an early filling of the ileum, triggering an enzymatic cascade that stimulates an autologous secretion of insulin in patients with pancreatic reserve.

This surgical technique results in the cure of type 2 diabetes (defined by the Diabetes American Association as a fasting glucose less than 100 mg/dl in venous plasma, a glycemia at 2 hours after an oral glucose overload with 75 g less than 140 mg/dl and HbA1c less than 6.5% and normal insulin levels in blood) without causing malnutritional states and maintaining the BMI between normal values and overweight and improving quality of life.

Ethics approval

The Clinical Research Ethics Committee of Aragon [Comité Ético de Investigación Clínica de Aragón (CEICA)], 16/03/2011, ref: C.I.EC10/028

Study design

Prospective randomized controlled clinical trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Type 2 diabetes


A five trocars laparoscopic surgical intervention, a gastric cross-section leaving a 300 ml gastric reservoir, a biliopancreatic derivation with a jejunoileal anastomosis at 120 cm from the ileocecal valve and a jejunal section at 320 cm from the ileocecal valve.

The pharmacological treatment for the control group will be the usual one used in clinical practice for the control of type 2 diabetic patients. This treatment includes antidiabetics and/or insulin.

The drug type, dose and administration frequency depends on the patient and its characteristics.
The more common antidiabetic treatments include the following ones: gliclazide, glimepiride, repaglinide, metformin, pioglitazone, rosiglitazone, sitagliptine, vildagliptine and exenatide.

Intervention type



Not Applicable

Drug names

Primary outcome measures

1. Normal glucose levels
2. Insulin blood level
3. Normal nutritional state assessed against calcium, iron, protein and vitamin metabolism
4. BMI between 20 and 30
5. Quality of life

Secondary outcome measures

1. Insulin production related hormones evolution (GIP, GLP1, ghrelin, neuropeptide YY)
2. Glucose metabolism (glucagon test, basal proinsulin)

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Patients diagnosed with type 2 diabetes
2. Between 18 and 60 years old
3. Body mass index (BMI) between 30 and 35
4. Less than 10 years of illness evolution
5. Subject to medical treatment (oral antidiabetics, and/or insulin) and without enough control
6. More than 2 years of medical treatment and adequate pancreatic reserve (haemoglobin glycosylated determination with a result of more than 7)

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Positive anti glutamic acid decarboxylase (GAD) antibodies
2. Patients diagnosed with type 2 diabetes controlled with one or two oral antidiabetics, preanesthetic evaluation between 4 or 5 Anesthetic Society of America criteria values (ASA)
3. Laparoscopic and surgery general contraindications

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Servicio de Cirugía General y del Aparato Digestivo

Sponsor information


Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)

Sponsor details

Avenida Gómez Laguna 25
Planta 3

Sponsor type

Research organisation



Funder type

Research organisation

Funder name

Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes